메뉴 건너뛰기




Volumn 28, Issue 9, 2001, Pages 879-881

Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections

Author keywords

Cidofovir; CMV; Stem cell transplant

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; PROBENECID;

EID: 0035193083     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703251     Document Type: Article
Times cited : (35)

References (11)
  • 2
    • 0006840760 scopus 로고    scopus 로고
    • Randomised, multicenter, open-label trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation (abstract). ICAAC: San Francisco,
    • (1999)
    • Reusser, P.1    Einsele, H.2    Lee, J.3
  • 6
    • 0034967683 scopus 로고    scopus 로고
    • Differences between the quantitative antigenemia assay and the cobas amplicor monitor quantitative PCR assay for detecting CMV viraemia in bone marrow and solid organ transplant patients
    • (2001) J Med Virol , vol.64 , pp. 275-282
    • Flexman, J.1    Kay, I.2    Fonte, R.3
  • 7
  • 10
    • 0033816267 scopus 로고    scopus 로고
    • Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: The HPMPC Peripheral Cytomegalovirus Retinitis Trial
    • The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group
    • (2000) AIDS , vol.14 , pp. 1571-1581


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.